posted on 2021-06-10, 18:36authored byXuan Gao, Peng Zhang, Kaimin Du, Manli Zhang, Ding Wen, Yu Lu, Jing Feng, Hongjie Zhang
A theranostic
nanoagent exhibits great promise to improve diagnostic
accuracy and therapy efficacy. Herein, a kind of theranostic nanoagent
based on poly(vinylpyrrolidone) (PVP)-protected ultrasmall Cu1.2O nanoparticles (Cu1.2O NPs) is developed by
a facile liquid reduction method. Attributed to high near-infrared
absorbance and good biocompatibility, Cu1.2O NPs have shown
significant potential for photothermal therapy. Moreover, Cu1.2O NPs with a satisfactory T1 relaxivity
coefficient (r1) can be well applied as
outstanding MRI contrast agents and exhibit excellent magnetic resonance
imaging (MRI) ability. In vivo treatments further
demonstrate that Cu1.2O NPs could be well used as multifunctional
theranostic nanoagents, which achieve precise MRI and a high photothermal
antitumor effect. It is expected to further promote the research and
application of copper-based nanoparticles as theranostic nanoagents
for cancer therapy.